Elanco Animal Health's Strong Q4 and Full Year 2025 Results with Upsurge in Innovation Goals In its recent report, Elanco Animal Health detailed strong financial results for Q4 and full year 2025, driven by innovation and growth, along with ambitious targets for 2026.

Elanco Animal Health's Strong Q4 and Full Year 2025 Results with Upsurge in Innovation Goals #United_States #Elanco_Animal_Health #Indianapolis #Credelio_Quattro #Befrena

Elanco's Credelio Quattro™ Receives FDA Approval for Canine Screwworm Treatment Elanco Animal Health announces that its product Credelio Quattro™ has received FDA's conditional approval for treating New World Screwworm in dogs, expanding treatment options.

Elanco's Credelio Quattro™ Receives FDA Approval for Canine Screwworm Treatment #USA #Indianapolis #Elanco #Credelio_Quattro #New_World_Screwworm

Elanco Animal Health Releases Strong Q3 2025 Results with Increased Outlook and Innovation Targets Elanco Animal Health showcases impressive Q3 2025 results, highlighting a revenue increase and strengthened innovation targets for the remainder of the year.

Elanco Animal Health Releases Strong Q3 2025 Results with Increased Outlook and Innovation Targets #United_States #Elanco_Animal_Health #Indianapolis #Credelio_Quattro #Experior

Elanco's Credelio Quattro Achieves Major Sales Milestone in Pet Health Industry Elanco Animal Health's Credelio Quattro has reached $100 million in sales, marking its place as a leading innovation in pet health treatments.

Elanco's Credelio Quattro Achieves Major Sales Milestone in Pet Health Industry #United_States #Elanco #Greenfield #Pet_Health #Credelio_Quattro

Elanco Animal Health Reports Strong Q2 2025 Results with Increased Revenue and Innovation Targets Elanco Animal Health announces impressive Q2 2025 financial performance, elevating revenue and innovation targets while enhancing their leverage ratio outlook.

Elanco Animal Health Reports Strong Q2 2025 Results with Increased Revenue and Innovation Targets #United_States #Elanco_Animal_Health #financial_results #Greenfield #Credelio_Quattro

Elanco Animal Health Delivers Strong Q1 Results and Optimistic 2025 Forecast Elanco Animal Health has reported a 1% revenue drop in Q1 2025, but remains optimistic with an upward revision in its annual revenue guidance, driven by favorable currency effects.

Elanco Animal Health Delivers Strong Q1 Results and Optimistic 2025 Forecast #United_States #Elanco_Animal_Health #Greenfield #Zenrelia #Credelio_Quattro

Elanco's Credelio Quattro™: A Revolutionary Solution for Parasite Protection in Pets Elanco Animal Health's newest product, Credelio Quattro™, offers unmatched parasite protection for dogs with its innovative formula. Discover its benefits today!

Elanco's Credelio Quattro™: A Revolutionary Solution for Parasite Protection in Pets #United_States #Elanco #Greenfield #Credelio_Quattro #parasite_protection

Legal Concerns for Investors of Elanco Animal Health as Lawsuit Looms A recent lawsuit against Elanco Animal Health Incorporated has raised concerns among investors, particularly regarding FDA approval timelines for Zenrelia and Credelio Quattro.

Legal Concerns for Investors of Elanco Animal Health as Lawsuit Looms #USA #San_Diego #Elanco_Animal_Health #Zenrelia #Credelio_Quattro